FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Etoposide Injection
Status: Currently in Shortage
»Date first posted: 01/24/2018
»Therapeutic Categories: Oncology

Expand all

Accord Healthcare Inc. (Revised 05/08/2018)

Company Contact Information:
866-941-7875

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
ETOPOSIDE INJ USP 20MG/ML 5ML (NDC 16729-114-31) Partially available. Full recovery expected August 2018. Increase demand for the product
ETOPOSIDE INJ USP 20MG/ML (Nova Plus) 5ML (NDC 16729-262-31) Partial availability from the week of 7/30/2018. Full recovery expected August 2018. Increase demand for the product
ETOPOSIDE INJ. USP 20MG/ML 25 ML (NDC 16729-114-08) Partially available. Full recovery expected August 2018. Increase demand for the product
ETOPOSIDE INJ. USP 20MG/ML 50 ML (NDC 16729-114-11) Partial availability from the week of 7/30/2018. Full recovery expected August 2018. Increase demand for the product

Fresenius Kabi USA, LLC (Revised 06/11/2018)

Company Contact Information:
888-386-1300

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
100 mg per 5 mL, 20 mg per mL, MDV (NDC 63323-104-05) Backordered. Next release anticipated June 2018. Manufacturing delay
500 mg per 25 mL, 20 mg per mL, MDV (NDC 63323-104-25) Backordered. Next release anticipated June 2018. Check wholesaler inventory Manufacturing delay
1 gram per 50 mL, 20 mg per mL, MDV (NDC 63323-104-50) Available Check wholesaler inventory Manufacturing delay

Teva Pharmaceuticals (Reverified 06/05/2018)

Company Contact Information:
800-545-8800

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
100 mg / 5 mL Multiple-dose Vials (NDC 0703-5653-01) Teva has limited quantities and product is being allocated. Periodic backorders are anticipated. Duration of the limited supply is unknown at this time.
500 mg / 25 mL Multiple-dose Vials (NDC 0703-5656-01) Teva has limited quantities and product is being allocated. Periodic backorders are anticipated. Duration of the limited supply is unknown at this time.
1 gram /50 mL Multiple-dose Vials (NDC 0703-5657-01) Marketing 50 mL size is not planned for an undetermined period of time. Shortage of an active ingredient

West-Ward Pharmaceuticals (New 06/20/2018)

Company Contact Information:
800-631-2174

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
20 mg/mL, 5 mL vial (NDC 0143-9510-01) This presentation is temporarily on backorder. Additional lots are scheduled to be manufactured and available in the July 2018 timeframe. Product will be made available as it is released. Demand increase for the drug
20 mg/mL, 25 mL vial (NDC 0143-9511-01) This presentation is temporarily on backorder. Additional lots are scheduled to be manufactured and available in the July 2018 timeframe. Product will be made available as it is released. Demand increase for the drug
20 mg/mL, 50 mL vial (NDC 0143-9512-01) This presentation is temporarily on backorder. Additional lots are scheduled to be manufactured and available in the July 2018 timeframe. Product will be made available as it is released. Demand increase for the drug

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English